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aetiology of community-acquired neonatal 
sepsis in low- and middle-income countries
Background 99% of the approximate 1 million annual neonatal 
deaths from life-threatening invasive bacterial infections occur in 
developing countries, at least 50% of which are from home births 
or community settings. Data concerning aetiology of sepsis in these 
settings are necessary to inform targeted therapy and devise man-
agement guidelines. This review describes and analyses the bacte-
rial aetiology of community-acquired neonatal sepsis in developing 
countries. 
Methods A search of Medline, Embase, Global Health and Web of 
Knowledge, limited to post-1980, found 27 relevant studies. Data 
on aetiology were extracted, tabulated and analysed along with data 
on incidence, risk factors, case fatality rates and antimicrobial sen-
sitivity.
Results The most prevalent pathogens overall were Staphylococcus 
aureus (14.9%), Escherichia coli (12.2%), and Klebsiella species 
(11.6%). However, variations were observed both between global 
regions and age-of-onset categories. Staphylococcus aureus and Strep-
tococcus pneumoniae were most prevalent in Africa, while Klebsiella 
was highly prevalent in South-East Asia. A notably higher prevalence 
of Group B Streptococcus was present in neonates aged 7 days or less. 
The highest case fatality rates were recorded in South-East Asia. Kleb-
siella species showed highest antimicrobial resistance.
Conclusion Data on community-acquired neonatal sepsis in devel-
oping countries are limited. Future research should focus on areas 
of high disease burden with relative paucity of data. Research into 
maternal and neonatal vaccination strategies and improved diagnos-
tics is also needed. All of this could contribute to the formulation of 
community-based care packages, the implementation of which has 
significant potential to lower overall neonatal mortality and hence 
advance progress towards the attainment of Millennium Develop-
ment Goal 4. 
Approximately 1 million deaths a year occurring in the neonatal period 
(0–28 days) are caused by infection, accounting for over 25% of global 
neonatal deaths and 10% of all mortality in infants under the age of 5 
(1); 99% of these deaths occur in developing countries (2). Neonatal sep-
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sis is classically defined as the presence of symptoms of 
sepsis in the neonatal period combined with bacteriologi-
cal isolation of an infectious agent from blood or cerebro-
spinal fluid (CSF) (3). It is classified as ‘early-onset’ if it 
occurs within the first 7 days of life and as ‘late-onset’ if it 
occurs after this time. Typically, early-onset sepsis is con-
sidered maternally-acquired, usually from the maternal 
genital tract, and late-onset sepsis is generally regarded to 
originate from the care-giving environment – either a 
healthcare or community setting. Consequently early- and 
late-onset sepses are also associated with different distri-
butions of pathogens (4). 
The majority of babies in developing countries are born at 
home and at least a half of neonatal deaths occur in home 
births (5). Reasons for this include poor health system cov-
erage or provision and limited or no access to referral fa-
cilities (6). There is significant evidence that in rural areas 
neonates often do not receive required healthcare and that 
this is associated with an increase in mortality (7). How-
ever, other reasons for the high prevalence of home births 
can be suggested, such as financial constraints. This is be-
cause even when health care services are available, and of 
respectable quality, they may still remain beyond the finan-
cial means of many (8). There are also potential sociocul-
tural issues related to the rejection of health care services 
for newborns, because research has demonstrated a high 
prevalence of refusal of hospital referrals by their families 
and highlighted the need for education programmes on ap-
propriate care seeking (9).
The predominance of home births in developing countries 
is not reflected in related research as this mainly provides 
data on neonatal sepsis in hospitals, a large percentage of 
which is nosocomial (10). There are several potential rea-
sons behind the lack of aetiological data on neonatal sepsis 
acquired in the community, including lack of sufficient lab-
oratory facilities in rural areas and also potentially low lev-
els of care seeking, resulting in much unreported morbid-
ity and mortality. This may particularly be true for the 
cases that occur in the areas without access to health care, 
or in areas with poorly developed care-seeking behaviour 
(4). This review is concerned specifically with the bacte-
rial aetiology of life-threatening, community-acquired neo-
natal sepsis (CANS). 
Pathogenesis and risk factors 
Due to their immature immune systems and incompletely 
developed skin barriers, neonates are more susceptible to 
infection (11). In developing countries, the likelihood of 
infection is increased due to other additional risk factors. 
Unsafe birthing practices are common, with only 35% of 
births in some of the least developed countries being at-
tended by a skilled birth attendant (12), often resulting in 
unhygenic practices such as delivery onto a unsterile floor, 
unsterile cord cutting and potentially unsafe cultural cus-
toms such as spreading dung on the newborn’s umbilicus 
(10). Other predisposing risk factors for infection in neo-
nates include low birth-weight, prematurity, prolonged 
rupture of membranes and a long delivery period (3). 
Health education can also be a problem with early detec-
tion of CANS in developing countries often being low, po-
tentially due to mothers failing to notice important symp-
toms and seek healthcare. The role of women in some 
societies is also an issue, with woman having a low social 
standing and a lack of autonomy resulting in delays in, or 
absence of, care seeking for infant’s health, poorer sanita-
tion and a decrease in access to healthcare facilities (10).
Management
Management of neonatal sepsis in a hospital setting is com-
monly through parenteral antibiotic therapy and support-
ive care, which has shown positive impacts (10). However, 
it is important to note that most neonates in developing 
countries do not receive this therapy because they do not 
have access to the necessary health services, or their par-
ents do not seek care. A recent review showed a significant 
reduction in mortality from CANS as a result of introduc-
ing perinatal care packages including injectable antibiotics 
to the community (6). Research shows that the aetiology 
of neonatal sepsis is continually evolving, and therefore 
continuing updating of aetiological data is necessary to in-
form appropriately targeted therapy (10). A previous re-
view of CANS showed a predominance of gram-negative 
organisms over gram-positive, with the main causative 
pathogens being Klebsiella species, Escherichia coli and 
Staphylococcus aureus (4). The focus of this review will be 
to provide updated data on the aetiology of CANS globally.
Prevention
In addition to efforts to improve diagnosis and treatment 
of CANS, efforts to prevent this life-threatening illness are 
also important to consider. A review of possible preventa-
tive interventions for improving neonatal health highlight-
ed a need for universal provision of antenatal care for moth-
ers in developing countries as a means of decreasing 
mortality from neonatal sepsis (13). This involves educat-
ing mothers about hygienic birth practice, promoting 
breast feeding and also detecting and treating important 
maternal risk factors for neonatal sepsis, such as asymp-
tomatic bacteriuria (13). Another important potential way 
to prevent neonatal sepsis is to train and provide adequate 
numbers of skilled birth attendants in the community (10).
Possibly one of the most important preventative interven-
tions after birth is early and exclusive breastfeeding. Breast 
milk contains important immunological factors, some of 
which have the potential to inhibit causative pathogens of V
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neonatal sepsis (11). This is a major issue, as recent re-
search has shown that only 37% of infants younger than 
six months of age in developing countries are exclusively 
breastfed (14). Consequently, promotion of breastfeeding 
in community settings is the subject of an extensive World 
Health Organization (WHO) strategy document (15).
International responses to neonatal sepsis
Neonatal sepsis is an important issue internationally, espe-
cially with relation to the United Nations Millennium De-
velopment Goals. Without a reduction in newborn deaths, 
of which sepsis is a major cause, the fourth goal of reduc-
ing mortality in children under five by two-thirds cannot 
be achieved (2). There is therefore a need to investigate 
prevention, diagnosis and treatment strategies and their 
potential for implementation or improvement globally (8).
Founded in 1992 by the WHO and the United Nations 
Children’s Fund (UNICEF), the Integrated Management of 
Childhood Illness initiative (IMCI) is an integrated ap-
proach to improving child health globally, which provides 
guidelines including curative and preventative elements in 
both healthcare and community settings. Rather than an 
individual disease-specific approach, IMCI has a wide and 
integrated strategy, aiming at addressing the varied risk fac-
tors for childhood illness (16). This approach is highly rel-
evant in the case of neonatal sepsis as the disease has many 
risk factors and can be both healthcare- and community-
acquired. In many settings where CANS is prevalent, high-
quality diagnostic facilities are not widely available and the 
determination of commonly observed clinical signs provid-
ed by IMCI guidelines could be key in increasing diagnosis 
of neonatal sepsis and improving health outcomes (10). 
Emerging antibiotic resistance is also important to consid-
er in relation to CANS. A recent review in this area con-
cluded that data concerning antibiotic resistance in CANS 
are very limited, but nevertheless highlighted potential 
cause for concern resulting from studies showing emerging 
resistance in Klebsiella species and E. coli although levels of 
resistance were noted to be lower than in hospital settings 
(17). Emerging antibiotic resistance is a major internation-
al concern (18) and the information about the aetiological 
spectrum of CANS and the prevalence of antibiotic resis-
tance among major causal pathogens are important to build 
a broader understanding of this important public health 
issue.
Aims of this study
The aims of this study were to provide information on the 
bacterial aetiology of CANS in developing countries and to 
discuss the implications of the information generated for 
future research and international child health policy in this 
field. The specific objectives of this systematic literature re-
view were to determine the bacterial aetiology of CANS in 
developing countries through systematic literature review, 
to investigate aetiological variations between global regions 
and different ages-of-onset and to explore potential sugges-
tions from information presented for future policy and re-
search.
METHODS
A review of published literature was undertaken using the 
electronic databases Medline, Embase, Global Health and 
Web of Knowledge. The search involved combinations of 
Medical Subject Headings (MeSH) and keywords in con-
junction with a search for each individual developing coun-
try. These were defined as low- or middle-income countries 
from World Bank classifications (19). Search terms used for 
Medline and Embase are shown in Table 1. Terms for oth-
Table 1 Search terms for Medline/Embase
1. Developing Countries/ or Algeria/ or Egypt/ or Libya/ or Morocco/ 
or Tunisia/ or Cameroon/ or Central African Republic/ or Chad/ or 
Congo/ or “Democratic Republic of the Congo”/ or Gabon/ or Bu-
rundi/ or Djibouti/ or Eritrea/ or Ethiopia/ or Kenya/ or Rwanda/ or 
Somalia/ or Sudan/ or Tanzania/ or Uganda/ or Angola/ or Botswa-
na/ or Lesotho/ or Malawi/ or Mozambique/ or Namibia/ or South 
Africa/ or Swaziland/ or Zambia/ or Zimbabwe/ or Benin/ or Burki-
na Faso/ or Cape Verde/ or Cote d’Ivoire/ or Gambia/ or Ghana/ or 
Guinea/ or Guinea-Bissau/ or Liberia/ or mail/ or Mauritania/ or Ni-
ger/ or Nigeria/ or Senegal/ or Sierra Leone/ or Togo/ or “Antigua 
and Barbuda”/ or Cuba/ or Dominica/ or Dominican Republic/ or 
Grenada/ or Haiti/ or Jamaica/ or “Saint Kitts and Nevis”/ or Saint 
Lucia/ or “Saint Vincent and the Grenadines”/ or Belize/ or Costa 
Rica/ or El Salvador/ or Guatemala/ or Honduras/ or Nicaragua/ or 
Panama/ or Mexico/ or Argentina/ or Bolivia/ or Brazil/ or Chile/ or 
Colombia/ or Ecuador/ or Guyana/ or Paraguay/ or Peru/ or Suri-
name/ or Uruguay/ or Venezuela/ or Antarctic Regions/ or Arctic 
Regions/ or Kazakhstan/ or Kyrgyzstan/ or Turkmenistan/ or Uz-
bekistan/ or Borneo/ or Cambodia/ or East Timor/ or Indonesia/ or 
Laos/ or Malaysia/ or Mekong Valley/ or Myanmar/ or Philippines/ 
or Thailand/ or Vietnam/ or Bangladesh/ or Bhutan/ or India/ or Sik-
kim/ or Afghanistan/ or Iran/ or Iraq/ or Jordan/ or Lebanon/ or Syr-
ia/ or Turkey/ or Yemen/ or Nepal/ or Pakistan/ or Sri Lanka/ or Chi-
na/ or Hong Kong/ or Macau/ or Tibet/ or Korea/ or “Democratic 
People’s Republic of Korea”/ or Mongolia/ or Taiwan/ or Albania/ or 
Lithuania/ or Bosnia-Herzegovina/ or Bulgaria/ or “Republic of Be-
larus”/ or “Macedonia (republic)”/ or Moldova/ or Montenegro/ or 
Russia/ or Bashkiria/ or Dagestan/ or Moscow/ or Siberia/ or Serbia/ 
or Ukraine/ or Yugoslavia/ or Armenia/ or Azerbaijan/ or “Georgia 
(republic)”/ or Melanesia/ or Fiji/ or Papua New Guinea/ or Vanuatu/ 
or Micronesia/ or Palau/ or Polynesia/ or Samoa/ or “Independent 
State of Samoa”/ or Tonga/ or Comoros/ or Madagascar/ or Mauri-
tius/ or Seychelles/ or Solomon Islands.mp. or Marshall Islands.mp. 
or (Sao Tome and Principe).mp. or Maldives.mp. or Tuvalu.mp. or 
(West Bank and Gaza).mp. or American Samoa/ or Romania/
2. exp Infant, Newborn/ or (newborn* or neonat*).tw.
3. exp sepsis/ or exp infection/ or (infection* or pathogen* or or-
ganism* or bacter* or etiology).tw.
4. Limit 3 to “etiology (sensitivity)” [Limit not valid in Embase; re-
cords were retained]
5. (neonat* adj3 sepsis).tw.
6. 2 and 4
7. 5 or 6
8. 1 and 7V
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er databases were slightly modified where necessary, to fit 
the search terms offered in the respective databases. Final 
searches on all databases were undertaken on 30 January 
2011. Searches were supplemented by screening reference 
lists of selected papers and including literature discovered 
that corresponded with inclusion criteria.
Inclusion and exclusion criteria
Although it started with no time limits, the review was 
eventually restricted to literature published after 1980, to 
limit the number of studies and to present current aetio-
logical data. No restrictions were used concerning publica-
tion type or language of publication. All life-threatening 
invasive bacterial infections (bacteraemia, pneumonia and 
meningitis) affecting infants of 0–90 days of age were in-
cluded.Studies reporting viral or fungal infection, nosoco-
mial infection, congenital infection or other infections such 
as ophthalmia neonatorum, malaria, tetanus or tuberculosis 
were excluded. All studies reporting CANS were included, 
along with studies where the setting or infection type re-
ported suggested CANS. A certain number of studies were 
found where it was thought that CANS was indicated, how-
ever. However, the study data were deemed inconclusive 
to justify this assumption with a sufficient degree of cer-
tainty. These studies were included for data extraction, but 
not for the final data analysis. Isolated organisms from both 
blood and CSF were included.
Studies reporting less than 50 cases were excluded, to in-
crease the potential to generalise from results and prevent 
large deviations in suggested prevalence due to small sam-
ple sizes and chance effects. Studies reporting the inci-
dence/prevalence of only one organism were also excluded, 
for the same reason of likely over-estimation and the effects 
of chance. Review articles were also excluded, because pri-
mary data were the focus of the review. These were, how-
ever, used as helpful sources of reference.
Data extraction
Data were extracted from all selected studies and compiled 
in Microsoft Excel spreadsheets. An overall table of study 
characteristics was formed (Supplementary Table 1) and 
individual tables for each study were compiled, charting 
quantities of organisms isolated from blood-culture proven 
CANS (Supplementary Table 2) (20–46). This data was 
further split into ≤7 days of life, 7–59 days of life and 60–
90 days of life based on the neonatal age at isolation of or-
ganism, henceforth described as age-of-onset (Supplemen-
tary Table 3). The first category corresponds to early-onset 
sepsis as described in the introduction. The second catego-
ry corresponds to late-onset sepsis but was expanded to fit 
the WHO definition of a ‘young infant’ (7–59 days). The 
third category includes any data after this period up to 90 
days. For several studies data were not reported in the cat-
egories described above and so it was necessary to redis-
tribute so as to standardise for analysis. Some studies re-
ported overlapping aetiological data for CSF and blood 
isolates (i.e. more than one isolate for an individual pa-
tient), in these studies it was decided to only extract data 
on blood isolates to avoid distortion of the results.
It was decided through the study of primary data descrip-
tions and previous reviews not to extract data for certain 
organisms, including Myma polymorpha and Micrococci sp. 
as they were deemed to be contaminants. Although previ-
ous studies have excluded altogether data specifying infec-
tion from coagulase-negative Staphylococci, which are 
known to be common opportunistic pathogens in hospital-
acquired infections, but are seen as likely to be contami-
nants in CANS (4,47), it was decided to extract data for 
these organisms but exclude them from summary tables. 
Data analysis
For the purpose of analysis, data tables from studies were 
separated into 6 WHO global regions as illustrated below 
(Figure 1). Summary tables using the aetiological catego-
ries above were assembled for each region and relative per-
centages of each organism calculated (Supplementary Ta-
ble 4). Tables for each region were then compiled, detailing 
only potentially pathogenic organisms so as to gain clearer 
insight into aetiology. Decisions on pathogenicity were 
based on those of previous reviews and also the informa-
tion from other published literature (2,4,48). The ‘other/ 
unspecified’ category for Gram-positives and Gram-nega-
tives was removed from potential pathogen tables along 
with the Non-stated/Undetermined category. 
Regional relative percentages for potential pathogens were 
calculated along with 95% confidence intervals and these 
were combined through meta-analysis to counteract issues 
with data bias and create an ‘All Regions’ category (Supple-
mentary Table 5). Either the fixed effect model (Mantel-
Haenszel method) or in cases of heterogeneity the random 
effect model (DerSimonian-Laird method) were used (49). 
Between-study heterogeneity was quantified by calculating 
the Q statistic with a p-value less or equal than 0.05 being 
the threshold (49). The meta-analysis results were unstable 
for several pathogens due to the small quantity of data, 
therefore it was decided for the purpose of analysis to use 
median and inter-quartile (IQ) range data from regional 
percentages for all potential pathogens and meta-analytical 
data of regional percentages for the cumulative ‘Potentially 
pathogenic Gram-positives/negatives’ columns.
As 30% of studies reported aetiological data using just 
numbers of positive isolates for each organism as a denom-
inator rather than the number of patients with positive iso-
lates for each organism, some studies reported more iso-V
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lates than the number of patients in their sample. Therefore 
it was deemed necessary to split aetiological data into that 
based on patients and that based on isolates so as to deter-
mine and analyse any differences. Other data on incidence, 
case fatality rates, risk factors for CANS and antimicrobial 
susceptibility patterns were extracted where available and 
analysed.
Quality control
To ensure quality control, another reviewer undertook an 
independent second data extraction of a certain proportion 
of this review’s selected studies, totaling 520 data points; 
100% of these were the same and therefore it was conclud-
ed that the standard of data reliability was likely to be high.
rESULTS
The literature search returned 16 789 studies whose titles 
and abstracts were reviewed for relevance. 103 were se-
lected for full text examination, however only 100 papers 
were sourced in full-text versions. Of these 31 were select-
ed for inclusion in the review. In addition, 3 studies were 
found from other studies’ reference lists and selected for 
inclusion, resulting in a total of 34 studies included in the 
review. Of these, 27 studies were deemed to be reporting 
data concerning CANS and 7 were considered to be less 
conclusive, possibly reporting neonatal sepsis acquired 
from another source (Supplementary Table 6) (50–56). 
To avoid potential compromising of final results it was de-
cided to extract data from these 7 papers however exclude 
them from overall analyses. The literature search process is 
outlined in Figure 2.
European Eastern Mediterranean
Americas
Africa
South-East Asia
Western Pacific
Figure 1 WHO Regions (adapted from Wikimedia Commons; 
http://commons.wikimedia.org/wiki/File:World_Health_Organisation_regional_offices.PNG). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Studies identified through  
search of Medline, Embase, 
Global Health, Web of Knowledge
(n=16789)
Additional studies identified  
through reference list
(n=3)
Titles and abstracts 
screened 
(n=16792)
Records excluded 
(n=16686 )
Full-text articles  
assessed for eligibility
(n=106)
Full-text articles  
excluded in accordance 
with inclusion/ 
exclusion criteria 
(n=72)
Data extracted (n=34)
Data inconclusive 
(extracted and presented 
in appendices) (n=7)
Studies included in 
qualitative synthesis
(n=27)
Studies included in 
quantitative synthesis 
(meta-analysis)
(n=27)
Figure 2 An overview of literature search results.
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Characteristics of the studies that were retained after the 
process of literature search as they met the minimum qual-
ity criteria are shown in Table 2. A full version of this table 
can be found in Supplementary Table 1. Of the 27 stud-
ies, only 2 presented community surveillance data. Anoth-
er 20 either presented CANS-specific or disaggregated non-
nosocomial data and the remaining 5 did not explicitly 
report CANS aetiology but were deemed suitable for inclu-
sion due to the infection type or study setting reported. 
Four studies were the primary data sources for a WHO 
Young Infants Study Group Multicenter Study (47), which 
presented overall data. However, in our study we treated 
each site as an independent data point, and we analysed 
the information from each study individually.
Aetiological data
Individual aetiological data from each study are presented in 
Supplementary Table 2. For the purpose of analyses, ae-
tiological data were split by WHO regions, and then by age-
of-onset. Table 3 is a summary table that contains data for 
all isolated organisms by region. Table 4 contains data for 
all potential pathogens isolated by region, both for age-of-
onset categories ≤7 days of life and 8–59 days. Data for the 
60–90 days of life category were excluded from these tables 
to fit with the WHO ‘young infant’ criteria. Full tables in-
cluding this data are presented in Supplementary Table 4. 
Figures 3 and 4 present the meta-analysis forest plot 
graphs for the potentially pathogenic Gram-positive and 
Gram-negative categories respectively. Forest plot graphs 
for all other potential pathogens are presented in Supple-
mentary Table 5.
The percentages from Table 4 on the six most commonly 
isolated organisms along with Group B Streptococci (GBS) 
are then illustrated in Figure 5. Group B Streptococci was 
included despite its relatively low prevalence so as to pro-
vide comparison with known high colonization rates ex-
perienced in many developed countries (57). Figure 6 dis-
Table 2 Study characteristics
Characteristic No.  
studies
WHO Region
Africa 11
Americas 1
Europe 2
Eastern Mediterranean 1
South-East Asia 7
Western Pacific 5
Length of study
< 1 Year 3
1–2 Years 9
3–4 Years 8
≥ 5 Years 5
Not reported 2
Number of studies active 
in particular time periods
1980–1985 2
1986–1990 5
1991–1995 13
1996–2000 11
2001–2005 10
2006–2010 2
Not reported 2
Culture category
Blood 16
CSF 5
Blood and/or CSF* 5
Urine/Other 2
Study denominator Isolates 8
Patients 19
Number of positive isolates
0–25 8
26–50 10
51–75 5
76–100 1
101–200 1
>200 2
Number of potentially  
pathogenic positive isolates
0–25 11
26–50 10
51–75 3
76–100 1
101–200 1
>200 1
CSF – cerebrospinal fluid
*One study also used antigen detection.
Figure 3 Forest plot of the summary estimate and 95% confidence inter-
val of the prevalence of potentially pathogenic Gram-positives. Analysis 
is based on 27 studies in the 5 WHO regions (Africa: 11 studies, Ameri-
cas: 1 study, Europe: 2 studies, Eastern Mediterranean: 1 study, South East 
Asia: 7 studies and Western Pacific: 5 studies). Weights are from random 
effects analysis. ES: estimate, 95% CI: 95% confidence interval; I-squared 
and p-value are measures for heterogeneity between the studies.
Figure 4 Forest plot of the summary estimate and 95% confidence inter-
val of the prevalence of potentially pathogenic Gram-negatives. Analysis 
is based on 27 studies in the 5 WHO regions (Africa: 11 studies, Ameri-
cas: 1 study, Europe: 2 studies, Eastern Mediterranean: 1 study, South East 
Asia: 7 studies and Western Pacific: 5 studies). Weights are from random 
effects analysis. ES: Estimate, 95% CI: 95% confidence interval; I-squared 
and p-value are measures for heterogeneity between the studies. 
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plays data from Table 4 of the relative proportions of 
gram-positive and gram-negative potential pathogens in 
each region.
Table 5 presents data of all organisms isolated in all regions 
categorised by different age-of-onset categories. Region-
specific age-of-onset data for potential pathogens are pre-
sented in Supplementary Table 3. Eight studies from 6 
countries in 4 regions (Africa, Europe, South-East Asia, 
Western Pacific) reported data for the category of neonates 
who were up to 7 days old. Data were presented in varying 
ways and in addition to aetiological data specified as sepsis 
occurring at ≤7 days of life, data reported as 4–6 days, 0–6 
days, 0–7 days, 0–5 days and ‘early-onset’ were also in-
cluded in this category. 
Figure 5 Percentage of selected 
potential pathogens in WHO 
regions. Numbers in parentheses 
indicate the total numbers of 
potential pathogens isolated for 
each region.
Figure 6 Distribution of Gram-positive and Gram-negative 
potential pathogens by region.
However, all studies (from 14 countries, and in all regions) 
reported data for the category of neonates and young in-
fants who were 8–59 days old. In addition to aetiological 
data specified as sepsis occurring at 8–59 days of life, data 
categorised as <2 months, 1–2 months, 8–60 days, 8–30 
days, 7–59 days, 7–55 days, 7–28 days and ‘late-onset’ or 
being from ‘neonates/newborns’ were also included. Final-
ly, five studies from five countries in two regions (Africa, 
Western Pacific) reported data for the category of infants 
60–90 days of age. In addition to aetiological data specified 
as sepsis occurring at 60–90 days of life, data categorised 
as 2–3 months, 31–90 days, 30–90 days, 30–59 days and 
1–3 months were also included.
Study denominator
Nineteen studies used patients as a denominator, while 8 
used isolates. Data on potential pathogens from all age-of-
onset categories and regions were split into those 2 group-
ings and displayed in Figures 7 and 8, respectively.
Other reported information
Ten studies from 8 countries in four regions reported data 
on CANS-specific case fatality rates, and these are detailed 
in Table 6 which furthermore contains CANS-specific in-
cidence data reported by 3 studies. With regard to the com-
monly reported risk factors for neonatal sepsis among pre-
mature or low birth weight neonates, only a single source 
of data was identified for each. Gatchalian and co-workers 
reported 46% incidence of CANS in low birth weight in-
fants in low resource settings (43), while Mondal and co-
workers quoted 22% of CANS incidence occuring in pre-
term  neonates  (38).  Culture  positivity  rates  varied 
significantly, with reported rates as high as 65% (41) and 
as low as 5% (26), or even 3% for some age groups (24). 
This could suggest significant differences among studies in 
inclusion criteria, case definition or capacity for accurate 
microbiological analysis, and therefore potentially data 
quality. Finally, 6 studies reported data concerning CANS-
specific antimicrobial sensitivity patterns. Sensitivity per-
centages to selected antimicrobials for the most prevalent 
pathogens are displayed in Table 7.
DISCUSSION
The overall data on CANS in low and middle income coun-
tries are very limited, with only 27 studies suitable for in-
clusion, many of which had small sample sizes and pro-
vided little data. This suggests a degree of caution over the 
overall validity of the review’s results. There was also sig-
nificantly fewer data for the age-of-onset categories ≤7 days 
of life and 60–90 days of life. The geographic focus of stud-
ies in certain global regions is another concern, with 17 of 
28 studies taking place in Africa or South-East Asia regions. 
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Although the majority of studies being conducted in Africa 
can be argued to fit with Africa having the highest neonatal 
mortality rates globally, it should be noted that seven out 
of ten African studies were based in Nigeria or Kenya, and 
there were little or no data for other countries with com-
parable neonatal mortality levels. Similarly, 6 out of 7 
South-East Asian studies were conducted in India, which 
again has high neonatal mortality rates. However, these are 
reportedly lower than in Pakistan, yet no studies were 
found from Pakistan (58). 
The largest numbers of studies found by this review were 
conducted between 1991 and 1995 and only 2 studies 
were relevant to the most recent period of 2006–2010, 
Table 5 Distribution of all isolates by age-of-onset
≤7 days of life 8–59 days of life 60–90 days of life
Organism Isolated N % (95% CI) N % (95%CI) N % (95%CI)
Staphylococcus aureus 33 11.7 (8.0–15.5) 268 15.0 (13.4–16.7) 1 2.3 (0.0–6.7)
Group A Streptococci/ Streptococcus pyogenes 4 1.4 (0.0–2.8) 50 2.8 (2.0–3.6) 8 18.2 (6.8–29.6)
Group B Streptococci  19 6.7 (3.8–9.7) 31 1.7 (1.1–2.4) 0 0.0 (–)
Group D Streptococci/ Enterococcus 4 1.4 (0.0–2.8) 13 0.7 (0.3–1.1) 0 0.0 (–)
Streptococcus Pneumoniae 13 4.6 (2.1–7.1) 93 5.2 (4.2–6.3) 14 31.8 (18.1–45.6)
Other/unspecified Streptococcus species 24 8.5 (5.3–11.8) 50 2.8 (2.0–3.6) 0 0.0 (–)
Other/ unspecified Gram-positives* 0 0.0 (–) 112 6.3 (5.2–7.4) 0 0.0 (–)
All Gram-positives 97 34.4 (28.9–39.9) 617 34.6 (32.4–36.8) 23 52.3 (37.5–67.0)
Klebsiella pneumoniae 22 7.8 (4.7–10.9) 232 13.0 (11.4–14.6) 2 4.5 (0.0–10.7)
Other/unspecified Klebsiella species 10 3.5 (1.4–5.7) 15 0.8 (0.4–1.3)  0 0.0 (–)
Escherichia coli 46 16.3 (12.0–20.6) 320 17.9 (16.2–19.7) 1 2.3 (0.0–6.7)
Pseudomonas species 22 7.8 (4.7–10.9) 166 9.3 (8.0–10.7) 1 2.3 (0.0–6.7)
Enterobacter species 10 3.5 (1.4–5.7) 59 3.3 (2.5–4.1) 0 0.0 (–)
Serratia species 0 0.0 (–) 40 2.2 (1.6–2.9) 1 2.3 (0.0–6.7)
Proteus species 6 2.1 (0.4–3.8) 7 0.4 (0.1–0.7) 0 0.0 (–)
Salmonella species 1 0.4 (0.0–1.0) 26 1.5 (0.9–2.0) 6 13.6 (3.5–23.8)
Haemophilus influenzae 2 0.7 (0.0–1.7) 30 1.7 (1.1–2.3) 4 9.1 (0.6–17.6)
Neisseria meningitidis 0 0.0 (–) 13 0.7 (0.3–1.1) 0 0.0 (–)
Acinetobacter species 19 6.7 (3.8–8.7) 113 6.3 (5.2–7.5) 3 6.8 (0.0–14.3)
Other/unspecified Gram-negatives** 42 14.9 (10.7–19.0) 59 3.3 (2.5–4.1) 1 2.3 (0.0–6.7)
All Gram-negatives 180 63.8 (58.2–69.4) 1080 60.5 (58.3–62.8) 19 43.2 (28.5–57.8)
Non-stated/Undetermined 5 1.8 (0.2–3.3) 87 4.9 (3.9–5.9) 2 4.5 (0.0–10.7)
Totals 282 100.0 (n/a) 1784 100.0 (n/a) 44 100.0 (n/a)
*Includes data for Aerococcus sp., Bacillus sp. and others.
** Includes data for Citrobacter sp., Moraxella sp., Shigella sp., Aeromonas sp. and others. Data were also extracted for coagulase- negative Staphylococci: 
≤7 days of life – 3 isolates, 7–59 days of life – 880 isolates, 60–90 days of life – 0 isolates.
Table 6 Reported case fatality rates and incidence data
Region Article Case fatality rate reported* Incidence data reported
Africa Berkley et al (22) 56% of ≤7 days of life, 26% of 8–59 days of life 1457/105 person years (for infants <1year old)
  Mulholland et al (28) 31% of 0–91 days of life –
  English et al (24) 27% of ≤7 days of life, 5% of 8–59 days of life –
  Muhe et al (27) 49% of 0–59 days of life –
  Campagne et al (23) 58% of 0–59 days of life –
Americas Weiss et al (30) – 421/105 person years (for infants <2months old)
South-East Asia Mondal et al (38) 32% of 0–59 days of life –
  Mathur et al (37) 70% of 0–59 days of life –
Europe Taskin et al (33) 5% of ≤7 days of life, 3% of 8–59 days of life –
Western Pacific Quiambao et al (45) 29% of 0–91 days of life –
Gatchalian et al (43) 26% of 0–91 days of life –
Choo et al (42) –  1571/105 live births
*Data were standardised to fit with age categories used in review.
highlighting the need for new research in this area and im-
plying potential issues with the representativeness of data 
presented here. Excluding studies before 1980 to narrow 
the literature review may have resulted in missing some 
relevant studies. Although the search was systematic, some 
studies after 1980 may have also been missed due to the 
potential of human error in screening results. In addition, 
several foreign language studies were excluded because it 
was not possible to extract enough information to include 
them in the review. Several studies had very low culture 
positivity rates, resulting in small numbers of organisms 
being reported. The potential to generalise results is lim-
ited by their small sample sizes. Some studies presented 
considerably larger numbers of isolated organisms than 
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Table 7 Percentage sensitivity patterns of most prevalent pathogens to selected antimicrobials
  Region Africa South-East Asia
Organism Antimicrobial Adejuyigbe et al (20) Muhe et al (27) Mathur et al (37) Panigrahi et al (39) Darmstadt et al (35) Tallur et al (41)
Escherichia 
coli
Amoxycillin (AMX) 60.0 – – – – –
Ampicillin (AMP) 40.0 100.0 – – 100.0 29.0
Cefotaxime (CTX) – – – – – 100.0
Ceftazidime (CAZ) – 100.0 – – 100.0 –
Ceftriaxone (CRO) – – – – 100.0 100.0
Ciprofloxacin (CIP) – – – – 100.0 –
Gentamicin (GEN) 80.0 100.0 – – 100.0 71.0
Imipenem (IMP)         100.0 –
Staphylococcus 
aureus 
Amoxycillin (AMX) 73.0 – – – – –
Ampicillin (AMP) – – – – 0.0 21.0
Cefotaxime (CTX) – – – – – –
Ceftazidime (CAZ) – – – – 66.7 –
Ceftriaxone (CRO) – – – – 90.0 –
Ciprofloxacin (CIP) – – – – 80.0 –
Gentamicin (GEN) 85.8 – – – 90.0 29.0
Imipenem (IMP) – – – – 90.0 –
Klebsiella 
species*
Amoxycillin (AMX) 0.0 – – – – –
Ampicillin (AMP) – – 10.0 – 0.0 25.5
Cefotaxime (CTX) – – – – – 76.5
Ceftazidime (CAZ) – – – 22.0 33.3 –
Ceftriaxone (CRO) – – 71.4 – 33.3 81.0
Ciprofloxacin (CIP) – – 64.8 11.0 66.7 –
Gentamicin (GEN) 100.0 – 42.8 – 66.7 59.5
Imipenem (IMP) –   100.0 – 100.0 –
*Averages were taken when more than one variant’s sensitivity patterns were reported.
others, thereby giving greater weight to their reported ae-
tiological data.
To analyse aetiological data by the age-of-onset, it was nec-
essary to standardise data into specific categories; however, 
these categories did not always fit with reported data. In 
certain cases it was therefore necessary to reassign and im-
pute data. This was not the case for the significant major-
ity of studies. Despite some of the limitations described 
above, data presented in this review should be generally 
robust and useful for planning international child health 
policy on tackling neonatal infections. 
Study design
Criteria for diagnosing neonatal sepsis varied significantly, 
providing inconsistencies in data and potential biases. 
Some studies included pneumonia and meningitis in this 
category, while others considered them indistinguishable 
from the data for sepsis. The criteria for excluding nosoco-
mial infections also differed, with several studies merely 
separating data into babies born in the study hospital and 
babies born elsewhere (and other studies not defining cri-
teria at all). The age-of-onset categories also were not fully 
consistent between studies, and there were some discrep-
ancies with definitions of ‘early-onset’ and ‘late-onset’ sep-
sis. Several studies did not collect data for all age-of-onset 
categories, therefore not providing a complete picture of 
CANS aetiology. Also, a certain number of studies split data 
into community-acquired and nosocomial, and into differ-
ent age-of-onset categories, but they did not combine these 
two categorisations. Still, in all cases we used the informa-
tion from other studies to impute the data and align it with 
the majority of studies, in order to prevent valuable infor-
mation from being lost. 
Although several studies explicitly reported excluding in-
fants who had received prior antimicrobial therapy, the ma-
jority of studies did not report inclusion or exclusion criteria 
relating to this factor. This is potentially an important issue 
as antimicrobial therapy prior to blood cultures being taken 
could significantly change aetiological patterns and therefore 
bias the reported data. Most studies reported data from ba-
bies who presented to primary facilities or outpatient ser-
vices of referral facilities. The aetiological distribution may 
differ from that of babies who are born at home and die be-
fore reaching hospital. Only two studies adopted a commu-
nity-surveillance approach that could counter this issue.
Culture positivity rates were reported to be considerably 
low by some studies, potentially indicating inadequate lab-
oratory facilities or high prior antimicrobial use. Future re-
views could potentially exclude these studies, but this 
would further decrease the amount of data. It is likely that 
the prevalence of certain pathogens such as Haemophilus in-
fluenzae is underestimated in many studies due to the sig-
nificant diagnostic capacity required to isolate these organ-
isms (4). For the same reason, it is possible that prevalence 
of less fastidious organisms such as S. aureus is overestimat-
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ed, due to comparitive ease of isolation. This is reinforced 
by a study that used the non-culture technique of antigen 
detection and reported significantly higher H. influenzae 
prevalence compared with many other studies (30).
Distribution of CANS pathogens  
in developing countries
This review suggests that the majority of organisms that 
cause CANS in low and middle income countries are Gram-
negative pathogens. The most commonly isolated are, in 
ranked order, S. aureus, E. coli and Klebsiella species. These 
results are similar to a previous review, where the order of 
prevalence was Klebsiella species, E. coli and S. aureus (4). 
The potential for significant comparisons of the regional 
distribution of potential pathogens is limited due to the 
paucity of data, particularly in the Eastern Mediterranean 
and Americas regions. Both Europe and Western Pacific 
regions are similar to the overall distribution with S. aureus, 
E. coli and Klebsiella species the most prevalent organisms. 
The Western Pacific region also displays a higher preva-
lence of Pseudomonas species compared with overall aggre-
gates. Europe has a high prevalence of Group D Streptococ-
ci. In the African region, S. aureus is seen as the most 
prevalent potential pathogen, followed by Streptococcus 
pneumoniae, which is only marginally less prevalent and is 
found in all age-of-onset categories. Notably, the prevalence 
of both Group A and Group B Streptococci is more than 
doubled in comparison to other regions. In the African re-
gion, unlike in any other region, 54.9% of potential patho-
gens isolated were Gram-positive. The Eastern Mediterra-
nean region also showed a relatively high prevalence with 
48% Gram-positive potential pathogens. This is important 
to consider, as some antibiotics are more effective against 
one than the other. South-East Asian region displayed a 
major predominance of Klebsiella species, followed by S. 
aureus, E. coli and Pseudomonas species. 
Although the distribution of potential pathogens is broad-
ly similar in ≤7 days of life and 8–59 days of life, GBS iso-
lates are notably more prevalent in the ≤7 days of life cat-
egory. This was potentially expected, as neonatal GBS 
infection is commonly taken to be maternally-acquired 
(59). This review reports a lower prevalence of GBS as a 
CANS pathogen in developing countries than previous re-
search (4). However, the prevalence of GBS neonatal sepsis 
in the first 7 days of life estimated by both this paper and 
previous review (4) is considerably lower than in devel-
oped countries (60). It is unclear whether a genuine aetio-
logical difference is present, or there is a bias because most 
cases of early-onset sepsis in developing countries are not 
being registered because infants die before reaching health 
facilities (61). This is potentially supported by Stoll and 
Schuchat, who reported similar rates of maternal GBS col-
onization in developing countries compared with devel-
oped countries (62). Culture-negative GBS neonatal sepsis 
has also been shown in previous studies to be high, poten-
tially as a result of maternal antibiotic therapy (63). This 
could result in underestimation of the burden of GBS neo-
natal sepsis if based on bacterial isolates.
The predominance of Gram-negative organisms and over-
all similar distribution of pathogens in the ≤7 days of life 
and the 8–59 days of life age-of-onset categories may con-
tradict the assumption that early-onset neonatal sepsis is 
mainly maternally acquired. One potential explanation for 
these similar distributions is bias resulting from the neces-
sary standardisation of primary data for analysis. However, 
this notion was also supported by another systematic re-
view (4) and therefore may potentially have implications 
for CANS prevention, highlighting the need for improved 
hygienic practices before, during and after birth. In addi-
tion, similar aetiologies between the two groups may sug-
gest that WHO ‘young infant’ guidelines (7–59 days) for 
management of sepsis could also be used for sepsis occur-
ring before this period.
Figure 7 Potential pathogens in studies using patients as 
denominator. Data labels indicate the number of isolates.
Figure 8 Potential pathogens in studies using isolates as 
denominator. Data labels indicate the number of isolates.
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Data for the post-young infant category of 60–90 days of 
life showed marked differences compared with that of ear-
lier age-of-onset categories, justifying the 7–59 day age 
group defined in WHO ‘young infant’ guidelines, because 
management is likely to be different for later ages-of-onset. 
There was a significantly higher relative prevalence of 
Group A Streptococci, S. pneumoniae, Salmonella species and 
H. influenzae, and an overall majority of Gram-positive or-
ganisms, as compared with the significant Gram-negative 
majorities in other categories. One potential reason for this 
may be a bias due to the small quantity of data for this cat-
egory. However, similar aetiological distributions are re-
ported by Zaidi et al. (4) and this notion could be of sig-
nificance and relevant for informing antibiotic therapy.
CANS compared with hospital-acquired 
neonatal sepsis
A recent review of hospital-acquired neonatal sepsis in de-
veloping countries showed a predominance of Gram-neg-
ative organisms with Klebsiella species most commonly iso-
lated, followed by S. aureus and then E. coli (5). This is 
similar to this review’s findings, suggesting potential simi-
larities in major pathogens between CANS and hospital-
acquired neonatal sepsis in developing countries. The hos-
pital-acquired neonatal sepsis review, however, showed 
GBS as far more frequent causative organism than in this 
review of CANS. This may be due to easier capture of GBS 
in hospital-born babies as the vast majority of cases pres-
ent within 48 hours of birth, whereas cases occuring in 
home-born babies may never have the opportunity to be 
diagnosed because of the fatal nature of this disease (60). 
Incidence, case-fatality, risk factors, 
diagnosis and treatment
CANS-specific incidence was reported in only 3 papers (3 
countries, 3 regions), and in different formats, ranging from 
421/100 000 person years for infants under 2 months to 
1571/100 000 live births. These data are insufficient to 
draw more general conclusions, and a similar lack of data 
was highlighted in a recent review of the burden of neona-
tal infections in developing countries (64). Lack of health-
care access and low levels of care-seeking lead to signifi-
cantly underestimation of CANS incidence in most studies 
(65), although community surveillance study designs may 
go some way to ameliorate this.
Data on Case Fatality Rates (CFRs) were also scarce, pre-
sented in only 10 studies (8 countries in 4 regions), with 
no data from the Americas and Eastern Mediterranean re-
gions. The potential for comparison of CFRs is also limited 
as they are significantly dependant on age-of-onset and se-
verity. However, the majority of studies reported CFRs of 
over 30%, with the overall CFR for developing countries 
seen to be as much as 20 times higher than that of devel-
oped countries. This is congruent with the estimate of 99% 
of neonatal deaths occurring in developing countries 
(1,60). Addressing reasons behind this gap and designing 
interventions to reduce its size are clear areas for policy de-
velopment and implementation.
Comparing studies that used patients as a denominator 
with those that used isolates, the distribution of potential 
pathogens is generally similar. Studies using isolates dis-
played a higher prevalence of S. aureus, potentially reflect-
ing multiple isolates for each patient rather than a differ-
ence in distribution. S. pneumoniae is significantly more 
prevalent in studies using patients as a denominator. This 
is most likely due to the fastidious nature of S. pneumoniae, 
which quickly autolyses in blood cultures, whereas S. au-
reus is a hardy pathogen and is known to be associated with 
prolonged bacteremia in many cases (66,67).
Only 2 studies reported data concerning CANS-specific 
risk factors (38,43). Data reported suggests that low birth 
weight and prematurity are both significant risk factors for 
CANS, but further risk factors should also be evaluated.
Six studies from two regions reported CANS-specific data 
on pathogen antimicrobial sensitivity. Data reported sug-
gests the main area of concern regarding antibiotic resis-
tance is that of Klebsiella species, which did not have 100% 
of isolates sensitive to any antibiotic apart from imipenem, 
and had high rates of resistance to third generation cepha-
losporins and aminoglycosides. This is a significant point 
to consider for targeted antibiotic therapy, especially in the 
South-East Asian region where Klebsiella species account 
for 45% of CANS. There is a need for further surveillance 
to accurately determine the sensitivity patterns of CANS 
pathogens, thereby aiding appropriate therapy and mini-
mising occurrence of resistance (17). Emerging antibiotic 
resistance is a global problem, and one potential reason for 
this is the wide availability of over-the-counter antibiotics 
in low and middle income countries (61). This is an im-
portant area to consider which to be combated requires 
both legislative and health promotion policies.
Coagulase-negative Staphylococci (CNS) were excluded as 
a contaminant in this and also in other reviews (4) and pri-
mary data sources (28), where no difference was reported 
in symptoms between patients with positive CNS blood 
cultures and those with entirely negative blood cultures 
(implying no pathogenicity). Conversely, in developed 
countries CNS are cited as major causative organisms of 
neonatal sepsis (60), although these data come from neo-
natal intensive care units and so further research is neces-
sary to establish consensus on CNS pathogenicity with re-
lation to CANS.
Overall data for the WHO Young Infants Study Group mul-
ticenter study (18) presented that 26% of S. pneumoniae 
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isolates were type 2, which is not included in current pneu-
mococcal conjugate vaccines. It is suggested that further 
research should be conducted in this area to establish this 
finding’s significance and inform future vacination devel-
opment and policy (18).
Implications for future research and 
international child health policy
This review has highlighted significant gaps in information 
concerning CANS in developing countries, and more re-
search into this area is urgently required. Due to the small 
number of studies reporting CANS aetiology it is necessary 
to further evaluate results presented here, to determine 
whether they are specific to these studies or reflect genuine 
aetiological distributions. The number of studies present-
ing data concerning 2005–2010 is five times less than those 
presenting data for 2000–2010, which suggests that the 
interest in this type of research is decreasing. 
Future research should focus on areas with high disease 
burden and a significant paucity of data, such as certain 
parts of South-East Asia and the Africa. Research into 
CANS occurring within the first 7 days of life is also sig-
nificantly needed as approximately 75% of neonatal deaths 
occur within this period (58), yet aetiological data is par-
ticularly scarce. Based on characteristics and limitations of 
studies analysed in this review, it is recommended that all 
future studies into CANS aetiology in developing countries 
follow the minimum criteria presented in Table 8. 
As a potential means of achieving greater and more repre-
sentative data for CANS in developing countries the estab-
lishment of several community surveillance sites is recom-
mended,  equally  situated  in  all  WHO  regions  and 
providing coordinated multicentre research data using the 
criteria above (58). Significant investment would be re-
quired to ensure adequate surveillance, but this would be 
warranted because reducing neonatal mortality – particu-
larly from infections – is crucial for progress towards Mil-
lennium Development Goal 4. Aetiological data from this 
review could be relevant when devising maternal and neo-
natal immunization strategies for developing countries. 
With mounting global levels of antibiotic resistance, im-
munization is becoming an increasingly important possible 
means of protecting neonates from infection (65). One po-
tential approach is passive immunization through maternal 
vaccination for which vaccines against GBS, S. pneumoniae 
and H. influenzae are in development at present (68). Al-
though vaccines against pathogens including Hepatitis B 
and Poliovirus are currently administered at birth in many 
countries, direct immunization of neonates is less well un-
derstood for the pathogens discussed in this review (69). 
There is also little current research into the use of estab-
lished childhood vaccines such as pneumococcal or H. in-
fluenzae type-b (Hib) in the neonatal period, despite some 
positive previous indications (70). This review encourages 
more research in this area and also suggests the need for 
investigation into vaccination possibilities for other patho-
gens prevalent in CANS in developing countries. Data from 
this review specifically supports research into maternal and 
neonatal pneumococcal vaccination as S. pneumoniae was 
highly prevalent in Africa, including the very first week of 
life. Serological issues with the conjugate vaccine in neo-
nates have however been highlighted above and these re-
quire further investigation.
This review also highlighted the need for identification, 
recognition and control of risk factors for CANS in devel-
oping countries. Low birth weight and prematurity are the 
only studied ones. Potential interventions to reduce the 
prevalence of these risk factors include improved maternal 
education and nutrition, prophylaxis/treatment of maternal 
malaria and other infections and overall improvement in 
socioeconomic conditions (71). Improved hygienic birth 
practices are also critical, emphasized by this review’s sug-
gestion that similar aetiological distributions between age 
categories may actually mean that most of the infections 
are acquired from the environment. In community settings, 
Table 8 Minimum preferred criteria for future research
Criteria Preferred standard
Study design Community surveillance
Case definition/ 
inclusion criteria
Use Darmstadt et al (35) algorithm for community-based neonatal assessment and diagnosis. Confirm microbiologically.
Exclude infants if received prior antimicrobial therapy.
Use explicit criteria for exclusion of nosocomial infection.
Data set
Use explicitly defined age-of-onset categories from WHO IMCI* guidelines.
Report site-of-birth of all cases.
Use highest feasible standard of microbiology facilities.
Record incidence per 105 live births in clearly defined study population.
Record case fatality rates for microbiologically confirmed sepsis.
Record data on risk factors.
Study denominator should be patients.
Test all isolates for antimicrobial sensitivity.
*WHO Integrated Management of Childhood Illness (16).
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improvements in hygienic practices can be linked to com-
munity and maternal health education and the training of 
traditional birth attendants (65). 
High case fatality rates reported in this review highlight the 
critical need for early diagnosis of severe neonatal illness 
for improving outcomes. There is a clear need for the im-
provement of current diagnostic methods and development 
of novel methods which would be feasible within the low 
resources settings. The WHO Integrated Management of 
Childhood Illness (IMCI) guidelines (16) use diagnostic 
algorithms to assess illness, an approach that is highly in-
dicated in community settings where diagnostic facilities 
are limited. A specific community-setting evaluation of a 
similar diagnostic algorithm showed high sensitivity and 
specificity (72), therefore suggesting that algorithms pres-
ent a significant potential for providing accurate commu-
nity-based diagnosis. Investments in dissemination of 
knowledge in this area and potential resultant policy ap-
proaches are encouraged. However, due to the varying ae-
tiological distributions and antibiotic sensitivities found in 
this review, the development of effective low-cost pathogen 
detection techniques is also implicated as therapy informed 
by this is likely to be more effective. The case for improved 
diagnostics is further emphasized by poor levels of culture 
positivity and suggestions of potentially biased information 
due to difficulties in isolating fastidious organisms.
Knowledge on aetiology is essential for appropriate and ef-
fective treatment. The regional and age-of-onset aetiologi-
cal variation presented in this review could be of use for 
local, national or regional bodies when devising case man-
agement guidelines. Further research would provide a 
more current picture of aetiological distribution and allow 
for regular guideline updates. The significant differences in 
aetiology between regions shown in this review suggest the 
benefits of a regional, rather than global, approach to case 
management guidelines. This review also reports poten-
tially significant antimicrobial resistance levels, especially 
among Klebsiella species, further supporting the need for 
community surveillance sites as suggested above to moni-
tor emerging resistance and inform attempts to minimize 
it. Due to the nature of CANS it is necessary to investigate 
the possibilities for effective low-cost treatment that is sim-
ple to administer in a community setting. For an antibiot-
ic regimen to be appropriate to community settings, effi-
cacy and safety even at an extended-interval dosing regimen 
is a desirable attribute (73). Penicillins and cephalosporins 
potentially fulfil those criteria. However, further evaluation 
of the efficacy of these and other antibiotics in community 
settings and against the spread of pathogens reported in 
this review is necessary to provide accurate reccomenda-
tions of appropriate therapy for CANS.
There is noteworthy potential for the implementation of 
community-based care packages to reduce CANS incidence 
and resulting mortality. A trial in India involving hygienic 
birth practices, regular home visits, simple algorithms for 
detection of neonatal illness and referral to healthcare fa-
cilities, or community-based treatment using oral or par-
enteral antibiotic therapy, was shown to be highly effective 
(74). All interventions were conducted or overseen by 
trained community health personnel and were combined 
with community health education programmes including 
birth preparedness and promotion of preventative neonatal 
care practices. Based on comparison with control villages, 
the study reported a 70% reduction in neonatal mortality 
rates (74). This model has been replicated in other loca-
tions with similar successes, suggesting that its combina-
tion of community-based prevention, diagnosis and treat-
ment  could  potentially  provide  a  cost-effective  and 
successful way of significantly reducing CANS incidence 
and mortality for many of the sites of studies analysed in 
this review (72,73,75,78). Implementation and evaluation 
of similar programmes could potentially be undertaken in 
conjunction with the community surveillance sites sug-
gested above.
It must be noted that accurate data collection on aetiolog-
ical distribution in low resource community settings can 
be a difficult task due to a lack of adequate microbiological 
facilities and trained staff (75). There are also considerable 
issues with the supply and quality of antimicrobials in cer-
tain developing areas (76) and a major requirement for ac-
curate aetiological data and improved treatment in devel-
oping countries can be seen to be that of health system 
strengthening (77). 
CONCLUSION
This systematic literature review of community-acquired 
neonatal sepsis (CANS) in developing countries suggests 
that the most common causative pathogens are S. aureus, 
E. coli and Klebsiella species, but with significant variation 
between regions and age-of-onset categories. This variation 
is important to monitor and consider for implementing ap-
propriate therapy, devising management guidelines and in-
forming related policy measures aimed at reducing CANS 
and overall neonatal mortality.
Several recommendations have been made to address is-
sues highlighted by this paper. Data concerning the aetiol-
ogy of CANS in developing countries are limited and sig-
nificant future research is necessary, focusing on areas of 
high disease burden where there is a paucity of data. The 
establishment of community surveillance sites conducting 
co-ordinated research using minimum criteria is suggested 
to monitor CANS aetiology and chart antimicrobial sensi-
tivity patterns. Other suggested areas of research include 
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investigations into neonatal immunization, risk factors for 
CANS and development of effective low-cost diagnostics 
for  improving  microbiologic  results.  Health  system 
strengthening is needed to enable positive improvements 
in accurate aetiological data and CANS prevention and 
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management. A reduction in overall neonatal mortality 
rates is important for achieving Millennium Development 
Goal 4 and there is a significant potential for the implemen-
tation of community-based care practices to achieve this 
with relation to CANS. 
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